, /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to litigation filed against the Company by Pfizer: “Metsera disagrees with the…
, /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced…
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at two…
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation…
MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of…
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business…
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and…
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions…
Credit: Institute for Bioengineering of Catalonia A pioneering technology has been developed that enables human kidney organoids to be produced in a scalable manner by allowing the organoids to be…
Credit: Steve Gschmeissner/Science Photo Library Cancer immunotherapies, such as immune checkpoint inhibitors (ICIs), are effective against many types of cancer. However, these treatments don’t work well for some tumors, including…